Does body mass index influence improvement in patient reported outcomes following total knee arthroplasty? A retrospective analysis of 3918 cases

Table 5 Multiple linear regression analysis of patient comorbidities and demographics impacting postoperative and pre/post-change (Δ) KOOS, JR scores

Baseline variable	Postoperative KOOS, JR estimate effect		Δ KOOS, JR estimate effect
Baseline variable	Estimate [95% CI]	P-value	Estimate [95% CI]	P-value
Age (years)	0.2 [0.1: 0.2]	< 0.001	− 0.1 [− 0.2: 0.0]	0.146
Female	− 0.6 [− 1.9: 0.8]	0.420	2.8 [1.0: 4.7]	0.003
BMI 18.5–25 kg/m² (reference)	1.0		1.0
BMI 25.01–30 kg/m²	− 2.2 [− 4.4: − 0.1]	0.045	0.8 [− 2.2: 3.8]	0.621
BMI 30.01–40 kg/m²	− 2.3 [− 4.: − 0.2]	0.034	3.6 [0.8: 6.5]	0.014
BMI > 40 kg/m²	− 1.9 [− 4.7: 0.8]	0.163	8.0 [4.3: 11.7]	< 0.001
White (reference)	1.0		1.0
African-American (Black)	− 4.9 [− 6.7: − 3.0]	< 0.001	− 1.3 [− 3.8: 1.2]	0.323
Asian	− 0.4 [− 3.4: 2.7]	0.803	2.2 [− 2.1: 6.4]	0.326
Other Race	− 3.2 [− 5.0: − 1.4]	< 0.001	0.8 [− 1.7: 3.2]	0.537
Myocardial Infarction	0.9 [− 3.4: 5.2]	0.683	0.3 [− 5.7: 6.3]	0.919
Cerebrovascular disease	− 2.9 [− 5.3: − 0.5]	0.018	− 2.1 [− 5.5: 1.2]	0.209
Chronic Pulmonary Disease	− 2.0 [− 3.7: − 0.3]	0.024	2.5 [0.1: 4.8]	0.045
Mild Liver Disease	− 0.1 [− 3.1: 2.9]	0.950	1.9 [− 2.4: 6.2]	0.388
DM without chronic complications	− 1.4 [− 3.1: 0.4]	0.128	0.0 [− 2.3: 2.3]	0.996
DM with chronic complications	− 3.9 [− 7.8: 0.1]	0.053	− 4.5 [− 10.0: 1.0]	0.110
Malignancy lymphoma leukemia	− 1.7 [− 3.7: 0.4]	0.107	− 2.5 [− 5.3: 0.2]	0.073
Metastatic solid tumor	1.8 [− 1.5: 5.1]	0.293	2.9 [− 1.7: 7.4]	0.210

Bold indicates statistical significance
BMI body mass index, KOOS, JR knee injury and osteoarthritis, joint replacement, CI confidence interval, DM diabetes mellitus

ISSN: 2234-2451